NASDAQ: POMPomdoctor Ltd Stock
$5.45+0.71 (+14.98%)
Updated Dec 5, 2025
POM Price
$5.45
Fair Value Price
-$3.34
Market Cap
$645.52M
52 Week Low
$3.35
52 Week High
$6.43
P/E
N/A
P/B
-1.95x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.24
Operating Cash Flow
N/A
Beta
0.94
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
POM Overview
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's business primarily consists of internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine POM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical Retailer
Industry Rating
F
POM
Ranked#2 of 5
Ranked#2 of 5
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.51 | B | |
| $0.61 | C | |
| $1.65 | D |
Be the first to know about important POM news, forecast changes, insider trades & much more!
POM News
Overview
Due Diligence Score
–
Industry Average (22)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how POM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
POM ($5.45) is overvalued by 263.25% relative to our estimate of its Fair Value price of -$3.34 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
POM ($5.45) is not significantly undervalued (263.25%) relative to our estimate of its Fair Value price of -$3.34 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
POM's short-term liabilities ($28.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
There are 30 more POM due diligence checks available for Premium users.
Valuation
POM fair value
Fair Value of POM stock based on Discounted Cash Flow (DCF)
Price
$5.45
Fair Value
-$3.34
Undervalued by
263.25%
POM ($5.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
POM ($5.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
POM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.95x
Industry
-9.26x
POM's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$6.1M
Liabilities
$78.4M
Debt to equity
-0.24
POM's short-term liabilities ($28.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
POM's long-term liabilities ($51.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
POM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
POM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
POM vs Pharmaceutical Retailer Stocks
Pomdoctor Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.